Literature DB >> 6726002

Erythromycin uptake and accumulation by human polymorphonuclear leukocytes and efficacy of erythromycin in killing ingested Legionella pneumophila.

M F Miller, J R Martin, P Johnson, J T Ulrich, E J Rdzok, P Billing.   

Abstract

Studies were undertaken to demonstrate the efficacy of erythromycin in killing Legionella pneumophila organisms that have been ingested by human polymorphonuclear leukocytes. With use of an electron microscope-autoradiography method in conjunction with an antibiotic-uptake assay, it was shown that [3H]-labeled erythromycin A base penetrated into the cytoplasm of human polymorphonuclear leukocytes in concentrations up to 24 times higher than the extracellular drug level. Similar studies using [14C]benzyl penicillin revealed that this antibiotic penetrated human polymorphonuclear leukocytes very poorly. Removal of erythromycin from the extracellular environment resulted in rapid leakage of radioactivity from the cells; an assay for bioactivity showed that this material was unaltered drug. Human polymorphonuclear leukocytes were permitted to ingest L. pneumophila and were then treated with erythromycin A base. The erythromycin killed the ingested legionellae, as evidenced by bacterial plate counts and morphological destruction of ingested organisms. These data clearly demonstrate the efficacy of erythromycin in killing susceptible intracellular pathogens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6726002     DOI: 10.1093/infdis/149.5.714

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Authors:  S Krasniqi; P Matzneller; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

Review 2.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

3.  Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.

Authors:  Felix Ratjen; Lisa Saiman; Nicole Mayer-Hamblett; Larry C Lands; Margaret Kloster; Valeria Thompson; Peggy Emmett; Bruce Marshall; Frank Accurso; Scott Sagel; Michael Anstead
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 4.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

Review 5.  Optimum treatment of intracellular infection.

Authors:  M Maurin; D Raoult
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

6.  Unpredictable influence of human serum on antimicrobial activity of erythromycin and three oxime ether macrolides.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

Review 7.  Intracellular concentrations of antibacterial agents and related clinical implications.

Authors:  J D Butts
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

8.  Susceptibility of Legionella spp. to quinolone derivatives and related organic acids.

Authors:  G Ruckdeschel; W Ehret; A Ahl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

9.  Effects of dirithromycin and erythromycylamine on human neutrophil degranulation.

Authors:  H Abdelghaffar; E M Mtairag; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1.

Authors:  P Rajagopalan-Levasseur; E Dournon; G Dameron; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.